Chemomab Therapeutics Ltd. Sponsored ADR

CMMB Healthcare Biotechnology

In the quarter to June 2026, EPS grew 25.0% and free cash flow grew 47.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

1.27 0.02 −1.55%
Market cap
$9.4M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Current Ratio
6.41 10.31 9.08 10.49

+8 more quarters

Net Debt/EBITDA
2.98 4.35 5.25 5.53
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow per Share
(0.47) 0.00 (1.75) 0.00
Book value per Share
1.09 1.34 1.93 0.45
Free Cash Flow
(3.75) — (11.13) —
Other line items

Show all line items

Columns are period end dates